BTIG Downgrades Akoya Biosciences Inc (AKYA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Morgan Stanley Downgrades Akoya Biosciences Inc (AKYA) to Equalweight
August 6, 2024 12:06 PM EDTMorgan Stanley analyst Tejas Savant downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Overweight to Equalweight with a price target of $3.00 (from $4.00).
The analyst comments "Guide lowered again despite in-line qtr as placements rebound falls short of expectations on weak capital... More
JPMorgan Downgrades Akoya Biosciences Inc (AKYA) to Neutral
August 6, 2024 2:54 AM EDTJPMorgan analyst Rachel Vatnsdal downgraded Akoya Biosciences Inc (NASDAQ: AKYA) from Overweight to Neutral.
The analyst comments: "This afternoon, Akoya (AKYA) reported 2Q results with revenue of $23.2M (roughly in line with the Street of $23.6M), driven by 51 instrument placements (bringing the total installed base to 1,264 vs. 1,213 in 1Q, +4% q/q). Looking ahead, the... More
Akoya (AKYA) Reports In-Line Q2 EPS, provides guidance
August 5, 2024 4:09 PM EDTAkoya (NASDAQ: AKYA) reported Q2 EPS of ($0.27), in-line with the analyst estimate of ($0.27). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $23.55 million.
GUIDANCE:
Akoya sees FY2024 revenue of $96-104 million, versus the consensus of $103.2... More
